Sedana Medical Announces Enrolment Of First Patient | Business News Update

Sedana Medical AB recently announced that the first patient has been enrolled in the company's US clinical studies. The two identical Phase III studies, INSPiRE-ICU 1 and 2, aim to confirm the efficacy and safety of inhaled sedation with isoflurane delivered via Sedaconda ACD and are expected to lead to a new drug application (NDA) filing at the US Food and Drug Administration (FDA) in the US. Read the full article here https://tinyurl.com/yt2ne7vt For more updates: Follow us on Twitter:   / wboutlook   Linkedin:   / worl.  . Facebook:   / wboutook   Instagram:   / wboutlook